Cytodyn Inc (CYDY)

[MelsDollars]

I would like to know why Patterson is still attempting to patent Leronlimab's MOA, treatment for covid-19 and using CYDY IP to do it? Everyone thinks he's just a pawn being used by the 13d group? Oh, it's much more than that. He has been trying to hitch his wagon to CYDY by any means necessary.

Here are some excepts from HIS patent application: https://patents.justia.com/patent/20210171646#history

Claims
1. A method of treating a subject for COVID-19, the method comprising:

administering to the subject a CCR5/CCL5 interaction inhibitor to treat the subject for COVID-19.

2. The method according to claim 1, wherein the COVID-19 is mild, moderate, severe or critical.

3. The method of according to any of claim 1 or 2, wherein the CCR5/CCL5 interaction inhibitor is a CCR5 antagonist.

4. The method according to claim 3, wherein the CCR5 antagonist is a specific binding member for CCR5.

5. The method according to claim 4, wherein the specific binding member for CCR5 is an antibody that specifically binds to CCR5.

6. The method according to claim 5, wherein the antibody that specifically binds to CCR5 is a humanized monoclonal antibody.

7. The method according to claim 6, wherein the antibody that specifically binds to CCR5 is Leronlimab (PRO 140).

55. The method according to any of claims 36 to 54, the method further comprising treating the subject having a critical or severe form of the disease by administering to the subject a CCR5/CCL5 interaction inhibitor.

56. The method according to claim 55, wherein the CRL5/CCL5 interaction inhibitor is a CCR5 antagonist.

57. The method according to claim 56, wherein the CCR5 antagonist is a specific binding member for CCR5.

58. The method according to claim 57, wherein the specific binding member for CCR5 is an antibody that specifically binds to CCR5.

59. The method according to claim 58, wherein the antibody that specifically binds to CCR5 is a humanized monoclonal antibody.

60. The method according to claim 59, wherein the antibody that specifically binds to CCR5 is Leronlimab (PRO 140).

61. The method according to claim 56, wherein the CCR5 antagonist is a small molecule.

* * *


83. The method according to any of claims 64 to 82, the method further comprising treating the subject having a critical or severe form of the disease by administering to the subject a CCR5/CCL5 interaction inhibitor.

84. The method according to claim 83, wherein the CCR5/CCL5 interaction inhibitor is a CCR5 antagonist.

85. The method according to claim 84, wherein the CCR5 antagonist is a specific binding member for CCR5.

86. The method according to claim 85, wherein the specific binding member for CCR5 is an antibody that specifically binds to CCR5.

87. The method according to claim 86, wherein the antibody that specifically binds to CCR5 is a humanized monoclonal antibody.

88. The method according to claim 87, wherein the antibody that specifically binds to CCR5 is Leronlimab (PRO 140)."